editors you can retarget across mutations sound close. who signs off on each version?
by Farah WeberReading the ESGCT write-ups. What stuck with me was David Liu talking about editors built so you can swap the target quickly across lots of different mutations, instead of designing a new drug for each one. Same few weeks, a prime editor was used inside a human body for the first time, if the headlines are right, and the FDA has a draft guidance on editing safety open for comments until 27 November. Genuinely good news. But a retargetable editor means every new guide is technically a new product. If a family's mutation needs version 37, does version 37 get its own tox package, or does it ride on the safety data from versions 1 to 36? My guess is regulators end up approving the process plus a release assay every batch has to pass. Is anyone here sending in comments?